Patents by Inventor Judith Campisi

Judith Campisi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7429457
    Abstract: A method for detection and prognosis of breast cancer and other types of cancer. The method comprises detecting expression, if any, for both an Id-1 and an Id-2 genes, or the ratio thereof, of gene products in samples of breast tissue obtained from a patient. When expressed, Id-1 gene is a prognostic indicator that breast cancer cells are invasive and metastatic, whereas Id-2 gene is a prognostic indicator that breast cancer cells are localized and noninvasive in the breast tissue.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: September 30, 2008
    Assignees: The Regents of the University of California, California Pacific Medical Center
    Inventors: Pierre-Yves Desprez, Judith Campisi
  • Publication number: 20060263809
    Abstract: Herein is described a method of detecting apoptotic cells and monitoring apoptosis in a caspase-independent manner. Cells are treated with a caspase inhibitor, and then a marker of apoptosis, such as a caspase-independent signaling protein, is detected for an extended period of time. When cells were suspended in the process of apoptosis and scored for apoptotic cells, the method was shown to be more sensitive than conventional assays. When apoptosis was induced by certain inhibitors, the method is capable of measuring cumulative background levels of apoptosis over a multi-day interval.
    Type: Application
    Filed: April 5, 2006
    Publication date: November 23, 2006
    Inventors: Judith Campisi, Joshua Goldstein
  • Publication number: 20060234273
    Abstract: A method for detection and prognosis of breast cancer and other types of cancer. The method comprises detecting expression, if any, for both an Id-1 and an Id-2 genes, or the ratio thereof, of gene products in samples of breast tissue obtained from a patient. When expressed, Id-1 gene is a prognostic indicator that breast cancer cells are invasive and metastatic, whereas Id-2 gene is a prognostic indicator that breast cancer cells are localized and noninvasive in the breast tissue.
    Type: Application
    Filed: March 27, 2006
    Publication date: October 19, 2006
    Applicants: The Regents of the University of California
    Inventors: Pierre-Yves Desprez, Judith Campisi
  • Publication number: 20020137064
    Abstract: A method for detection and prognosis of breast cancer and other types of cancer. The method comprises detecting expression, if any, for both an Id-1 and an Id-2 genes, or the ratio thereof, of gene products in samples of breast tissue obtained from a patient. When expressed, Id-1 gene is a prognostic indicator that breast cancer cells are invasive and metastatic, whereas Id-2 gene is a prognostic indicator that breast cancer cells are localized and noninvasive in the breast tissue.
    Type: Application
    Filed: September 14, 2001
    Publication date: September 26, 2002
    Inventors: Pierre-Yves Desprez, Judith Campisi
  • Patent number: 6409648
    Abstract: The present invention provides a novel telomere associated protein (Trf1-interacting nuclear protein 2 “Tin2”) that hinders the binding of Trf1 to its specific telomere repeat sequence and mediates the formation of a Tin2-Trf1-telomeric DNA complex that limits telomerase access to the telomere. Also included are the corresponding nucleic acids that encode the Tin2 of the present invention, as well as mutants of Tin2. Methods of making, purifying and using Tin2 of the present invention are described. In addition, drug screening assays to identify drugs that mimic and/or complement the effect of Tin2 are presented.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: June 25, 2002
    Assignee: The Regents of the University of California
    Inventors: Judith Campisi, Sahn-Ho Kim
  • Patent number: 5965543
    Abstract: Recombinant polynucleotides have expression control sequences that have a senescence responsive element and a minimal promoter, and which are operatively linked to a heterologous nucleotide sequence. The molecules are useful for achieving high levels of expression of genes in senescent cells. Methods of inhibiting expression of genes in senescent cells also are provided.
    Type: Grant
    Filed: April 17, 1997
    Date of Patent: October 12, 1999
    Assignee: Geron Corporation
    Inventors: Judith Campisi, Alessandro Testori
  • Patent number: 5795728
    Abstract: The present invention provides a biomarker system for the in vivo and in vitro assessment of cell senescence. In the method of the present invention, .beta.-galactosidase activity is utilized as a means by which cell senescence may be assessed either in vitro cell cultures or in vivo.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 18, 1998
    Assignee: The Regents of the University of California
    Inventors: Goberdhan P. Dimri, Judith Campisi, Monica Peacocke
  • Patent number: 5491069
    Abstract: The present invention provides a biomarker system for the in vivo and in vitro assessment of cell senescence. In the method of the present invention, .beta.-galactosidase activity is utilized as a means by which cell senescence may be assessed either in in vitro cell cultures or in vivo.
    Type: Grant
    Filed: February 18, 1994
    Date of Patent: February 13, 1996
    Assignee: The Regents of the University of California
    Inventors: Goberdhan P. Dirmi, Judith Campisi, Monica Peacocke